Kuala Lumpur, Malaysia – November 5th, 2009 Hai Kang Life Corporation Limited (HKLife) is a winner of the prestigious Frost & Sullivan Best Practices Award for Production Differentiation Excellence Award for In-Vitro Diagnostics of the year.
Frost & Sullivan Best Practices Award is presented each year to a company that has demonstrated effective strategy, leadership and innovation in the healthcare and technologies industries. Hai Kang Life was rigorously selected from a highly competitive field of competitors for creating advanced technologies that will catalyze healthcare industry in the future and for showing outstanding achievement in technological innovation and strategic product development
This award has come at an appropriate time when the Hong Kong Government is strongly supporting and nurturing the development of innovation and technology, and testing and certification, two of the six key industries in which Hong Kong has a competitive advantage to provide for future economic growth.
Accepting the award, Professor Albert Yu, Chairman and CEO of HKLife said, “It is a great honour to receive this prestigious award from Frost & Sullivan who is regarded as one of the most distinguished business research and consultancy firms in the world.”
“They have recognized the importance of Asian biotechnology and our company’s mission to develop innovative technologies. We aim to build a strong Hong Kong capability to win in this highly competitive global knowledge market.”
“The devotion of our company team has been essential, overcoming the commercialization difficulties we have experienced. I hope we can all appreciate the enormous beneficial impact high technology products will have on modern clinical diagnostics, global healthcare and disease surveillance.”
“Our EFADchip product is the result of ten years dedicated commitment to developing Lab-on-a-Chip, a device system that can detect DNA molecules of viruses and bacteria or genetic markers related to disease-causing genes in minutes, greatly speeding up diagnosis, effectively leading to early treatment of conditions and prevention of infectious disease outbreaks,” added Dr. Terence Lau, Chief Operating Officer.
”Furthermore, the EFADchip product offer key advantages in our development of Lab-on-a-Chip technology system such that infectious diseases like Influenza can be tested and screened without the need to transport samples to specialized laboratories which is particularly useful for remote areas of the world.”
”The Asian clinical diagnostics market is growing rapidly and characterized by the need for increased and simplified Point of Care testing. In this dynamic market, Hai Kang Life’s EFADchip based technology gives the company a competitive edge as it enables its customers to simplify patient care models by allowing diagnosis and treatment to be performed in a single visit,” stated Sohini Mitra, Research Manager of Frost & Sullivan’s healthcare practice.
“Fabricated using material that enables stability under varying environmental conditions, the EFADchip provides users with a combination of shortened testing times, accurate and sensitive results, convenience, and enhanced treatment decision making – all of which benefit patients in terms of cost and disease management Addressing needs for both physicians and patients, the EFADchip based technology has the potential to position the company as a front runner in the in -vitro diagnostics market.”
HKLife’s commitment to revolutionizing the practice of clinical diagnostics, providing effective platforms for point-of-care applications is already evident through its track record in market development success of molecular diagnostic technology for surveillance of infectious animal and clinical diseases. In rapid response to the 2009 novel H1N1 influenza outbreak, HKLife released a self-contained MOBILE FIELD UNIT, extending the company’s diagnostic technology capabilities to comprehensively serve the needs of the remote community. And now, HKLife’s innovative solution to affordable Point-of-Care diagnostics is being realized with EFADchip technology, bringing high quality molecular diagnostics to the global community and paving the way to personalized medicine.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas of leadership, technological innovation and strategic product development. Industry leading analysts adopt a ten-step process of research methodology, comparing market participants and measuring performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
About Frost & Sullivan:
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. There are up to 150 healthcare consultants and analysts in Asia Pacific region. To find out more, please visit http://www.frost.com.
About Hai Kang Life Corporation Limited:
Hai Kang Life Corporation Limited, formerly known as Hong Kong DNA Chips, was established with independent research funding in 1999. The company is strategically positioned at the hub of Asian biotechnology, equipped with the most advanced research and production facilities in both Beijing and Hong Kong. Strong working relationships with academic institutions, government and industry partners have created a solid foundation for business success. The world-class team of scientists, engineers and technologists, supported by a highly esteemed Scientific Advisory Board, is committed to maintaining HKLife’s position at the forefront of bio-business, leveraging best practices from both East and West. Further information about Hai Kang Life Corporation Limited can be found at: www.haikanglife.com
